PE20051155A1 - Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos - Google Patents
Compuestos de imidazol para el tratamiento de trastornos neurodegenerativosInfo
- Publication number
- PE20051155A1 PE20051155A1 PE2005000313A PE2005000313A PE20051155A1 PE 20051155 A1 PE20051155 A1 PE 20051155A1 PE 2005000313 A PE2005000313 A PE 2005000313A PE 2005000313 A PE2005000313 A PE 2005000313A PE 20051155 A1 PE20051155 A1 PE 20051155A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- treatment
- alkenyl
- neurodegenerative disorders
- imidazole compounds
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 3,5-DIFLUOROPHENYL Chemical class 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I DONDE A ESTA AUSENTE O ES SO2, ENTRE OTROS; R1 ES ALQUILO C1-C20, ALQUENILO C2-C20, ALQUENOXI C2-C20, ENTRE OTROS; R2 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, CICLOALQUENILO C3-C8, ENTRE OTROS; R3 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, HALO; R6 ES H, ALQUILO C1-C6, ALQUILENO C2-C6, HALO, ENTRE OTROS; R7 ES H, ALCOXI C1-C20, ALQUILO C1-C20, ENTRE OTROS. TAMBIEN REFERIDA A UN PROCEDIMIENTO PARA PREPARAR ESTOS COMPUESTOS CUYOS PREFERIDOS SON: ESTER METILO DEL ACIDO 3-(4-{2-[2-(3,5-DIFLUOROFENIL)ACETILAMINO]PENTANOILAMINO}IMIDAZOL-1-IL)BUTIRICO; ESTER METILICO DEL ACIDO 3-{4-[2-(2-HIDROXI-3-METILBUTIRILAMINO)PENTANOILAMINO]IMIDAZOL-1-IL}-3-METILBUTIRICO; ENTRE OTROS. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE Ab-PEPTIDOS Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS NEUROGENERATIVOS Y/O NEUROLOGICOS, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55562304P | 2004-03-23 | 2004-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20051155A1 true PE20051155A1 (es) | 2006-01-28 |
Family
ID=34961257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000313A PE20051155A1 (es) | 2004-03-23 | 2005-03-18 | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos |
Country Status (42)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005007717D1 (de) * | 2004-03-23 | 2008-08-07 | Pfizer Prod Inc | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen |
| JP2009508934A (ja) * | 2005-09-22 | 2009-03-05 | ファイザー・プロダクツ・インク | 神経障害治療のためのイミダゾール化合物 |
| MY149143A (en) | 2006-01-18 | 2013-07-15 | Amgen Inc | Thiazole compounds as protien kinase b (pkb) inhibitors |
| DE102006048042A1 (de) * | 2006-10-11 | 2008-04-17 | Bayer Healthcare Ag | Acylaminoimidazole und Acylaminothiazole |
| ES2447940T3 (es) * | 2007-10-15 | 2014-03-13 | The Salk Institute For Biological Studies | Métodos para el tratamiento de varias enfermedades y afecciones, y compuestos útiles para los mismos |
| WO2009093463A1 (ja) * | 2008-01-23 | 2009-07-30 | Taiho Pharmaceutical Co., Ltd. | 神経細胞死抑制剤 |
| WO2010096371A2 (en) | 2009-02-18 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds which modulate the cb2 receptor |
| EP2403835A1 (en) * | 2009-03-03 | 2012-01-11 | Pfizer Inc. | Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators |
| US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| EP2523936A1 (en) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
| US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
| RU2465273C2 (ru) * | 2010-08-31 | 2012-10-27 | Общество С Ограниченной Ответственностью "Биофарм-Меморейн" | ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| WO2013055386A2 (en) | 2011-10-03 | 2013-04-18 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| WO2015092614A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Inc. | Activating notch alterations in breast cancer |
| CN107406445B (zh) | 2015-02-03 | 2019-12-24 | 辉瑞公司 | 新颖环丙苯并呋喃基吡啶并吡嗪二酮类 |
| US10294237B2 (en) | 2015-06-22 | 2019-05-21 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic heterocyclic amide derivative |
| EP3312170A4 (en) * | 2015-06-22 | 2018-12-12 | Sumitomo Dainippon Pharma Co., Ltd. | 1,4-di-substituted imidazole derivative |
| US10898469B2 (en) | 2016-02-26 | 2021-01-26 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazolylamide derivative |
| SG10201913331VA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| SG11202010579XA (en) | 2018-06-01 | 2020-12-30 | Novartis Ag | Binding molecules against bcma and uses thereof |
| US20210196681A1 (en) * | 2018-08-27 | 2021-07-01 | Universiteit Maastricht | Selective presenilin-2 gamma-secretase inhibitors |
| JP2022538237A (ja) | 2019-06-24 | 2022-09-01 | ノバルティス アーゲー | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 |
| KR20250030524A (ko) * | 2019-08-09 | 2025-03-05 | 화이자 인코포레이티드 | (s)-2-(((s)-6,8-디플루오로-1,2,3,4-테트라하이드로나프탈렌-2-일)아미노)-n-(1-(2-메틸-1-(네오펜틸아미노)프로판-2-일)-1h-이미다졸-4-일)펜탄아미드의고체 상태 형태 및 이의 용도 |
| US11884634B2 (en) | 2019-08-09 | 2024-01-30 | Pfizer Inc. | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
| EP4010322B1 (en) * | 2019-08-09 | 2025-11-05 | Pfizer Inc. | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
| US20220348560A1 (en) * | 2019-10-02 | 2022-11-03 | Kainos Medicine, Inc. | N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient |
| AU2021271318B2 (en) | 2020-05-13 | 2025-10-30 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
| CA3194925A1 (en) | 2020-09-14 | 2022-03-17 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
| US20240041884A1 (en) | 2020-12-07 | 2024-02-08 | Cellestia Biotech Ag | Pharmaceutical Combinations for Treating Cancer |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| WO2022253794A2 (en) | 2021-06-02 | 2022-12-08 | Cellestia Biotech Ag | Method for treating an autoimmune and inflammatory disease |
| EP4396159A1 (en) | 2021-09-01 | 2024-07-10 | Springworks Therapeutics, Inc. | Synthesis of nirogacestat |
| US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
| EP4429661A1 (en) | 2021-11-08 | 2024-09-18 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| CN118302412A (zh) * | 2021-11-23 | 2024-07-05 | 梯瓦制药国际有限责任公司 | Nirogacestat盐的固态形式 |
| EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| WO2023174390A1 (zh) * | 2022-03-17 | 2023-09-21 | 苏州科睿思制药有限公司 | 尼罗司他二氢溴酸盐的晶型及其制备方法和用途 |
| IL316750A (en) | 2022-05-20 | 2025-01-01 | Springworks Therapeutics Inc | Treatments with Nirogesstat |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4512A (en) * | 1846-05-09 | Smut-machine | ||
| US50314A (en) * | 1865-10-03 | Improvement in telegraph-cables | ||
| DE1236426B (de) * | 1960-08-25 | 1967-03-09 | Dolomitwerke Gmbh | Verfahren zur Wasseraufbereitung |
| US5401851A (en) | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| JPH07101958A (ja) | 1992-10-16 | 1995-04-18 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
| DE19629816A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| US5760246A (en) * | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| US6329342B1 (en) * | 1997-08-19 | 2001-12-11 | Eli Lilly And Company | Treatment of congestive heart failure with growth hormone secretagogues |
| ZA987383B (en) | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| ZA987385B (en) | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
| US6639076B1 (en) * | 1998-08-18 | 2003-10-28 | Eli Lilly And Company | Growth hormone secretagogues |
| CO5160260A1 (es) * | 1999-02-19 | 2002-05-30 | Lilly Co Eli | Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido |
| US6828331B1 (en) * | 1999-02-19 | 2004-12-07 | Eli Lilly And Company | Growth hormone secretagogues |
| US6323315B1 (en) * | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| DE10019755A1 (de) | 2000-04-20 | 2001-11-08 | Bayer Ag | Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten |
| AU2001264977B2 (en) | 2000-05-30 | 2005-04-14 | Merck & Co., Inc. | Melanocortin receptor agonists |
| GT200100147A (es) * | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| JP2002059707A (ja) * | 2000-08-23 | 2002-02-26 | Bridgestone Corp | 空気入りタイヤ及び空気入りタイヤの製造方法 |
| AU2002223500A1 (en) * | 2000-11-17 | 2002-05-27 | Novo-Nordisk A/S | Glucagon antagonists/inverse agonists |
| EP2305648A1 (en) | 2001-12-21 | 2011-04-06 | Novo Nordisk A/S | Amide derivatives useful as glucokinase activators |
| TW200301698A (en) | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
| BRPI0311812B8 (pt) | 2002-06-05 | 2021-05-25 | Bristol Myers Squibb Co | antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso |
| MXPA05003432A (es) * | 2002-10-09 | 2005-07-05 | Pfizer Prod Inc | Compuestos pirazoles para el tratamiento de trastornos neurodegenerativos. |
| AU2003265068A1 (en) * | 2002-10-09 | 2004-05-04 | Pfizer Products Inc. | Thiazole compounds for the treatment of neurodegenerative disorders |
| JP2006182648A (ja) | 2003-04-08 | 2006-07-13 | Dai Ichi Seiyaku Co Ltd | ７員複素環誘導体 |
| WO2004099200A1 (en) * | 2003-05-12 | 2004-11-18 | Pfizer Products Inc. | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders |
| BRPI0413245A (pt) * | 2003-08-01 | 2006-10-03 | Pfizer Prod Inc | compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos |
| CA2534529A1 (en) * | 2003-08-06 | 2005-02-24 | Pfizer Products Inc. | Oxazole compounds for the treatment of neurodegenerative disorders |
| MXPA06001845A (es) * | 2003-08-21 | 2006-05-04 | Pfizer Prod Inc | Compuestos para el tratamiento de trastornos neurodegenerativos. |
| US7348968B2 (en) * | 2003-12-02 | 2008-03-25 | Sony Corporation | Wireless force feedback input device |
| GB0329275D0 (en) | 2003-12-18 | 2004-01-21 | Merck Sharp & Dohme | Therapeutic treatment |
| DE602005007717D1 (de) | 2004-03-23 | 2008-08-07 | Pfizer Prod Inc | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen |
| US7232820B2 (en) * | 2004-04-01 | 2007-06-19 | Pfizer Inc | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders |
| US20050222227A1 (en) * | 2004-04-01 | 2005-10-06 | Pfizer Inc | Oxazole-amine compounds for the treatment of neurodegenerative disorders |
| US7309709B2 (en) * | 2004-04-01 | 2007-12-18 | Pfizer Inc. | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders |
| US7163942B2 (en) * | 2004-04-01 | 2007-01-16 | Pfizer Inc. | Sulfonamide compounds for the treatment of neurodegenerative disorders |
| US7384968B2 (en) * | 2004-04-01 | 2008-06-10 | Pfizer Inc. | Thiazole-amine compounds for the treatment of neurodegenerative disorders |
| US7220865B2 (en) * | 2004-04-01 | 2007-05-22 | Pfizer Inc | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders |
| JP2009508934A (ja) * | 2005-09-22 | 2009-03-05 | ファイザー・プロダクツ・インク | 神経障害治療のためのイミダゾール化合物 |
-
2005
- 2005-03-11 DE DE602005007717T patent/DE602005007717D1/de not_active Expired - Lifetime
- 2005-03-11 BR BRPI0509069A patent/BRPI0509069B8/pt active IP Right Grant
- 2005-03-11 JP JP2007504496A patent/JP4054845B2/ja not_active Expired - Lifetime
- 2005-03-11 DK DK05708746T patent/DK1730119T3/da active
- 2005-03-11 SI SI200530339T patent/SI1730119T1/sl unknown
- 2005-03-11 EP EP05708746A patent/EP1730119B1/en not_active Expired - Lifetime
- 2005-03-11 AT AT05708746T patent/ATE399155T1/de active
- 2005-03-11 UA UAA200610159A patent/UA83899C2/uk unknown
- 2005-03-11 NZ NZ549331A patent/NZ549331A/en not_active IP Right Cessation
- 2005-03-11 HR HR20080375T patent/HRP20080375T3/xx unknown
- 2005-03-11 PT PT05708746T patent/PT1730119E/pt unknown
- 2005-03-11 EA EA200601494A patent/EA011689B1/ru not_active IP Right Cessation
- 2005-03-11 CN CN2005800093217A patent/CN1934091B/zh not_active Expired - Lifetime
- 2005-03-11 RS RSP-2008/0351A patent/RS50595B/sr unknown
- 2005-03-11 PL PL05708746T patent/PL1730119T3/pl unknown
- 2005-03-11 ES ES05708746T patent/ES2308441T3/es not_active Expired - Lifetime
- 2005-03-11 KR KR1020067019625A patent/KR100814599B1/ko not_active Expired - Lifetime
- 2005-03-11 CA CA002560580A patent/CA2560580C/en not_active Expired - Lifetime
- 2005-03-11 WO PCT/IB2005/000659 patent/WO2005092864A1/en not_active Ceased
- 2005-03-11 US US11/078,898 patent/US7342118B2/en not_active Expired - Lifetime
- 2005-03-11 GE GEAP20059630A patent/GEP20084420B/en unknown
- 2005-03-11 AU AU2005225635A patent/AU2005225635B2/en not_active Expired
- 2005-03-11 AP AP2006003727A patent/AP2379A/xx active
- 2005-03-18 SV SV2005002055A patent/SV2006002055A/es unknown
- 2005-03-18 TW TW094108466A patent/TWI372146B/zh not_active IP Right Cessation
- 2005-03-18 HN HN2005000115A patent/HN2005000115A/es unknown
- 2005-03-18 PE PE2005000313A patent/PE20051155A1/es not_active Application Discontinuation
- 2005-03-21 GT GT200500060A patent/GT200500060A/es unknown
- 2005-03-21 DO DO2005000040A patent/DOP2005000040A/es unknown
- 2005-03-22 UY UY28817A patent/UY28817A1/es not_active Application Discontinuation
- 2005-03-22 AR ARP050101116A patent/AR049875A1/es not_active Application Discontinuation
- 2005-03-22 NL NL1028598A patent/NL1028598C2/nl not_active IP Right Cessation
- 2005-03-23 PA PA20058627201A patent/PA8627201A1/es unknown
-
2006
- 2006-08-21 ZA ZA2006/06957A patent/ZA200606957B/en unknown
- 2006-08-21 IL IL177594A patent/IL177594A0/en active IP Right Grant
- 2006-09-21 CR CR8644A patent/CR8644A/es unknown
- 2006-09-22 TN TNP2006000300A patent/TNSN06300A1/fr unknown
- 2006-09-22 EC EC2006006879A patent/ECSP066879A/es unknown
- 2006-09-22 MA MA29336A patent/MA28481B1/fr unknown
- 2006-10-09 IS IS8550A patent/IS8550A/is unknown
- 2006-10-18 NO NO20064726A patent/NO338263B1/no unknown
-
2007
- 2007-06-13 JP JP2007156459A patent/JP2007291123A/ja active Pending
-
2008
- 2008-01-09 US US11/971,272 patent/US7795447B2/en active Active
- 2008-09-17 CY CY20081101001T patent/CY1108347T1/el unknown
-
2010
- 2010-03-12 US US12/723,204 patent/US7951958B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20051155A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
| PE133999A1 (es) | Derivados de acido hidroxamico como inhibidores de metaloproteasas de matriz (mmp) | |
| PE20051146A1 (es) | Compuestos heterociclicos anticitocina | |
| PE20080319A1 (es) | Dihidrotienopirimidinas como agentes inhibidores de pde-4 | |
| PE20040640A1 (es) | Compuestos de tiazol como inhibidores de la enzima gamma secretasa | |
| PE20030856A1 (es) | Esteres hidroxamato del acido n-(4-fenilsustituido)-antranilico | |
| PE20081359A1 (es) | Compuestos de azabenzotiofenil como inhibidores de la quinasa mek | |
| PE20060215A1 (es) | 4-fenilamino-quinazolin-6-il-amidas | |
| PE20040762A1 (es) | Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer | |
| IT1231413B (it) | Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht | |
| PE20120355A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| PE20061303A1 (es) | Composicion farmaceutica que comprende oxaprozina | |
| IS7170A (is) | Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra | |
| PE20081135A1 (es) | Derivados que contienen sulfamoilo y sus usos | |
| PE20050232A1 (es) | Metodo y composiciones para tratar la artritis reumatoide | |
| FI942381A0 (fi) | Aryylisubstituoituja heterosyklisiä yhdisteitä | |
| PE20081545A1 (es) | Derivados de sulfonamida como inhibidores de acido graso sintasas | |
| PE20061065A1 (es) | Derivados de piridazina como agentes inhibidores de esteaoril-coa desaturasa | |
| PE20060283A1 (es) | Compuestos inmunosupresores y composiciones | |
| PE20050131A1 (es) | Derivados de benzoimidazol como agentes antiproliferativos | |
| PE20060315A1 (es) | Compuestos de tiazol como moduladores de ppar | |
| PE20040898A1 (es) | Nuevos compuestos derivados de pirimidina | |
| WO2005092895A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists | |
| PE20061013A1 (es) | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias | |
| PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |